# Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer

> **NCT05079360** · PHASE2 · WITHDRAWN · sponsor: **Veru Inc.**

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Sabizabulin
- **DRUG:** Exemestane monotherapy, exemestane plus everolimus, or selective estrogen receptor modulator

## Key facts

- **NCT ID:** NCT05079360
- **Lead sponsor:** Veru Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2023-03-15
- **Primary completion:** 2024-03-30
- **Final completion:** 2024-05-26
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decided to halt and will potentially reopen in the future.
- **Last updated:** 2023-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05079360

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05079360, "Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT05079360. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*